EU/3/10/754

Table of contents

About

Please note that this product was withdrawn from the Union Register of orphan medicinal products in January 2021 on request of the sponsor.

On 27 July 2010, orphan designation (EU/3/10/754) was granted by the European Commission to Bioarctic Neuroscience AB, Sweden, for heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device made from alpha-calcium sulphate hemihydrate) for the treatment of traumatic spinal cord injury.

In September 2016, Bioarctic Neuroscience AB changed name to BioArctic AB.

Key facts

Active substance
Heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device made from alpha-calcium sulfate hemihydrate)
Disease / condition
Treatment of traumatic spinal cord injury
Date of first decision
27/07/2010
Outcome
Withdrawn
EU designation number
EU/3/10/754

Sponsor's contact details

BioArctic AB
Warfvinges väg 35
SE-112 51 Stockholm
Sweden
Tel. + 46 7 34411798
E-mail: gillian@albanyregulatory.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating